CEO Collard: How this Cary company’s value went from $200M to $800M

When Craig Collard first took the reins as president and CEO of Veloxis Pharmaceuticals in 2016, he painted a picture to investors of cornering a steady patient-market with an improved version of a generically-available treatment.